NEJM reports positive results for larotrectinib against TRK-fusion cancer

(University of Colorado Anschutz Medical Campus) 55 patients representing 17 cancer types tested positive for TRK fusion and were treated with larotrectinib. Overall response rate was 75 percent.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news